UroGen Pharma (URGN) Debt Ratio (2022 - 2026)

UroGen Pharma (URGN) has reported Debt Ratio for 5 consecutive years, with 0.75 the latest figure, recorded in Q1 2026.

• Quarterly Debt Ratio rose 51.5% year-over-year to 0.75 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.75 (up 51.5% YoY) and the FY2025 annual result came in at 0.61, up 43.09% from the prior year.
• Debt Ratio climbed to 0.75 in Q1 2026 per URGN's latest filing, from 0.61 in the prior quarter.
• Over the last five years, Debt Ratio for URGN reached as high as 1.03 in Q2 2023 and fell as low as 0.35 in Q2 2024.
• A 5-year average of 0.58 and a median of 0.55 in 2023 frame the typical range for Debt Ratio.
• Annual changes were most pronounced in 2023 — Debt Ratio jumped 111.58% — and 2024, when it slumped 66.33%.
• Year by year, Debt Ratio stood at 0.72 in 2022, then decreased by 23.15% to 0.55 in 2023, then slipped by 22.91% to 0.43 in 2024, then jumped by 43.09% to 0.61 in 2025, then rose by 22.54% to 0.75 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.75, 0.61, and 0.66 for Q1 2026, Q4 2025, and Q3 2025 respectively.